Coherus Biosciences | CHRS - Current Assets


Coherus Biosciences reported $133.79M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Akebia Therapeutics USD 229.55M 13.93M Jun/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Baxter International USD 6.99B 142M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Fujifilm JPY 1.72T 2.2B Mar/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Merck USD 36.68B 1.66B Jun/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Pacira USD 615.21M 100.25M Jun/2026
Perrigo USD 2.45B 260.7M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Teva Pharmaceutical Industries USD 13.76B 50M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026
Xencor USD 523.21M 40.36M Jun/2026
Zoetis USD 6.36B 118M Jun/2026